Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
BioWorld1mon
Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases
Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The ...
The Globe and Mail1mon
ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration
NanoVation Therapeutics' next-generation lipid nanoparticle platforms enable the efficient nucleic acid delivery to a variety of tissues. To efficiently target immune cells, NanoVation ...
Business Wire11d
PopVax Announces 1.15 Million USD in Funding from the Bill & Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...
Business Wire11d
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...